Fabrizio Benedetti

Jan 9, 2025 | passo.uno | Fabrizio Benedetti

I think all technical writers, at some point or another, feel the urge to base their work on something more systematic than “it’s just the way folks documented stuff since forever”. Toolkits and frameworks provide content types, which is immensely valuable when you know what you want to write, but starting from there is like buying a hammer without knowing that half of the work you’ll do is turning screws.

Oct 11, 2024 | nature.com | Florian Huber |Marion Arnaud |Fabrizio Benedetti |Jonathan Thevenet |Johanna Chiffelle |Markus K Muller | +7 more

AbstractThe accurate identification and prioritization of antigenic peptides is crucial for the development of personalized cancer immunotherapies. Publicly available pipelines to predict clinical neoantigens do not allow direct integration of mass spectrometry immunopeptidomics data, which can uncover antigenic peptides derived from various canonical and noncanonical sources.

Oct 11, 2024 | nature.com | Florian Huber |Marion Arnaud |Fabrizio Benedetti |Jonathan Thevenet |Johanna Chiffelle |Markus K Muller | +7 more

AbstractThe accurate identification and prioritization of antigenic peptides is crucial for the development of personalized cancer immunotherapies. Publicly available pipelines to predict clinical neoantigens do not allow direct integration of mass spectrometry immunopeptidomics data, which can uncover antigenic peptides derived from various canonical and noncanonical sources.

Apr 24, 2024 | nature.com | Matteo Morotti |Alizée J. Grimm |Helen Hope |Marion Arnaud |David Barras |Catherine Ronet | +14 more

AbstractExpansion of antigen-experienced CD8+ T cells is critical for the success of tumour-infiltrating lymphocyte (TIL)-adoptive cell therapy (ACT) in patients with cancer1. Interleukin-2 (IL-2) acts as a key regulator of CD8+ cytotoxic T lymphocyte functions by promoting expansion and cytotoxic capability2,3.